Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer

[1]  Leah M Chase,et al.  Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. , 2018, Cancer discovery.

[2]  J. Hainsworth,et al.  Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Nuciforo,et al.  Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights , 2017, Molecular oncology.

[4]  T. T. Poulsen,et al.  Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors , 2017, Clinical Cancer Research.

[5]  Meilin Wang,et al.  Plasma Mesothelin as a Novel Diagnostic and Prognostic Biomarker in Colorectal Cancer , 2017, Journal of Cancer.

[6]  L. Alpert,et al.  Anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma. , 2017 .

[7]  F. Meric-Bernstam,et al.  Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. , 2016, Cancer discovery.

[8]  V. Torri,et al.  Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[9]  G. Mills,et al.  Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  A. El-Hawary,et al.  Aberrant Expression of Calretinin, D2–40 and Mesothelin in Mucinous and Non-Mucinous Colorectal Carcinomas and Relation to Clinicopathological Features and Prognosis , 2016, Pathology & Oncology Research.

[11]  Michel Sadelain,et al.  Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. , 2016, Cancer discovery.

[12]  P. Nuciforo,et al.  High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti‐HER2 therapy , 2015, Molecular oncology.

[13]  Y. Bang,et al.  Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH , 2016, Gastric Cancer.

[14]  W. El-Deiry,et al.  Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites , 2015, Cancer biology & therapy.

[15]  S. Barni,et al.  FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study. , 2015, Clinical colorectal cancer.

[16]  Andrew M. Gross,et al.  ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer , 2015, PloS one.

[17]  C. Desmedt,et al.  Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Wei-Li Liao,et al.  Mass spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: Comparison to IHC and FISH , 2015, bioRxiv.

[19]  Aleksandra Markovets,et al.  Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.

[20]  Dong Wang,et al.  Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum–paclitaxel chemotherapy , 2014, Cancer Chemotherapy and Pharmacology.

[21]  T. Veenstra,et al.  Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue , 2014, PloS one.

[22]  S. Hewitt,et al.  Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue. , 2013, The Journal of molecular diagnostics : JMD.

[23]  D. Faller,et al.  Targeting the RAS oncogene , 2013, Expert opinion on therapeutic targets.

[24]  P. Li,et al.  ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy , 2013, British Journal of Cancer.

[25]  H. Lenz,et al.  TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials , 2011, The Pharmacogenomics Journal.

[26]  M. Moran,et al.  Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor Tissue , 2012, Clinical Proteomics.

[27]  M. Pollheimer,et al.  Keratin 7 expression in colorectal cancer – freak of nature or significant finding? , 2011, Histopathology.

[28]  Yuan Qi,et al.  Multifactorial approach to predicting resistance to anthracyclines. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  T. Conrads,et al.  Differential proteomic analysis of late-stage and recurrent breast cancer from formalin-fixed paraffin-embedded tissues. , 2011, Journal of proteome research.

[30]  O. Krakovska,et al.  mTRAQ‐based quantification of potential endometrial carcinoma biomarkers from archived formalin‐fixed paraffin‐embedded tissues , 2010, Proteomics.

[31]  John R Yates,et al.  Mass spectrometry in high-throughput proteomics: ready for the big time , 2010, Nature Methods.

[32]  J. Reid,et al.  Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  David L. Tabb,et al.  Performance Metrics for Liquid Chromatography-Tandem Mass Spectrometry Systems in Proteomics Analyses* , 2009, Molecular & Cellular Proteomics.

[34]  Christoph H Borchers,et al.  Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma , 2009, Nature Biotechnology.

[35]  N. Funel,et al.  PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Francesca Molinari,et al.  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. , 2009, Cancer research.

[37]  Jinsam You,et al.  LC/MS-Based Quantitative Proteomic Analysis of Paraffin-Embedded Archival Melanomas Reveals Potential Proteomic Biomarkers Associated with Metastasis , 2009, PloS one.

[38]  Nobuo Ochi,et al.  Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival , 2008, BMC gastroenterology.

[39]  J. Moldvay,et al.  The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas , 2008, Pathology & Oncology Research.

[40]  G. Fountzilas,et al.  Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study , 2008, BMC Cancer.

[41]  F. Cavalli,et al.  PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients , 2007, British Journal of Cancer.

[42]  Harvey J. Motulsky,et al.  Detecting outliers when fitting data with nonlinear regression – a new method based on robust nonlinear regression and the false discovery rate , 2006, BMC Bioinformatics.

[43]  Brian L Hood,et al.  Proteomic Analysis of Formalin-fixed Prostate Cancer Tissue*S , 2005, Molecular & Cellular Proteomics.

[44]  T. Molina,et al.  Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin , 2005, Modern Pathology.

[45]  T. Veenstra,et al.  Liquid Tissue: proteomic profiling of formalin-fixed tissues. , 2005, BioTechniques.

[46]  Chantal Wouters,et al.  An exploratory study , 2003 .

[47]  S. Groshen,et al.  ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  H. Niitani,et al.  [Phase II study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.